Efficacy and Safety Evaluation of Human Growth Hormone Therapy in Patients with Idiopathic Short Stature in Korea - A Randomised Controlled Trial.

Journal: European endocrinology
Published Date: Oct 15, 2019

Abstract

BACKGROUND: This trial evaluated the efficacy and safety of growth hormone (GH) therapy (Norditropin®; Novo Nordisk, Bagsværd, Denmark) in paediatric patients with idiopathic short stature (ISS) in Korea.

Authors

  • Min Ho Jung
    Department of Pediatrics, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Byung-Kyu Suh
    The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea.
  • Cheol Woo Ko
    Kyungpook National University Hospital, Daegu, South Korea.
  • Kee-Hyoung Lee
    Korea University Anam Hospital, Seoul, South Korea.
  • Dong-Kyu Jin
    Samsung Medical Center, Sung Kyun Kwan University, Seoul, South Korea.
  • Han-Wook Yoo
    Asan Medical Center, Seoul, South Korea.
  • Jin Soon Hwang
    Ajou University Hospital, Suwon, South Korea.
  • Woo Yeong Chung
    Inje University Busan Paik Hospital, Busan, South Korea.
  • Heon-Seok Han
    Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, South Korea.
  • Vinay Prusty
    Novo Nordisk Pharma Gulf FZ-LLC, Dubai, United Arab Emirates.
  • Ho-Seong Kim
    Severance Hospital, Yonsei University Health System, Seoul, South Korea.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals